Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

British Journal of Clinical Pharmacology

Volumn 68, Issue 4, 2009, Pages 535-545

  Krishna, Rajesh ^a   Garg, Amit ^a   Panebianco, Deborah ^a   Cote, Josee ^a   Bergman, Arthur J ^a   Van Hoydonck, Pascale ^a   Laethem, Tine ^a   Van Dyck, Kristien ^a   Chen, Jingjing ^a   Chavez Eng, Cynthia ^a   Archer, Laura ^a   Lutz, Ryan ^a   Hilliard, Deborah ^a   Snyder, Karen ^a   Jin, Bo ^a   Van Bortel, Luc ^b   Lasseter, Kenneth C ^c   Al Huniti, Nidal ^d   Dykstra, Kevin ^d   Gottesdiener, Keith ^a   Wagner, John A ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c PharmaNet Development Group Inc   (United States)

^d PHARSIGHT CORPORATION   (United States)

Author keywords

Age; CETP inhibition; Diet; Gender; Obese status

Indexed keywords

ANACETRAPIB; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHOLESTEROL ESTER TRANSFER PROTEINS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FASTING; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; OXAZOLIDINONES; SEX FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70350788822     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03465.x     Document Type: Article

References (23)

1. Knopp R. Drug treatment of lipid disorders. N Engl J Med 1999 341 : 498 511.
2. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Finding in 356,222 primary screens of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986 256 : 2823 2828.
3. Kannel WH, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham Study. Ann Intern Med 1979 90 : 85 91.
4. Campbell CY, Riverra JJ, Blumenthal JS. Residual risk in statin-treated patients: future therapeutic options. Curr Cardiol Rep 2007 9 : 499 505.
5. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993 34 : 1255 1274.
6. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 357 : 2109 2122.
7. O'Neill EA, Sparrow CP, Chen Y, Eveland S, Frantz-Wattley B, Milot D, Sinclair PJ, Ali A, Lu Z, Smith CJ, Taylor G, Thompson CF, Anderson MS, Cumiskey A, Rosa R, Strain J, Peterson LB. Identification and characterization of anacetrapib (MK-0859): a novel CETP inhibitor abstract]. XVI Int Symp Drugs Affecting Lipid Metabolism New York, NY, 2007.
8. Forrest MJ, Bloomfield D, Briscoe RJ, Ehrhart J, Hershey JC, Ma X, Peterson LB, Siegl PK, Sinclair PJ, Stevenson AS, Sun S-Y, Vargas HM, Walker M III., Sparrow CP. Torcetrapib-induced blood pressure elevation is independent of cholesteryl ester transfer protein inhibition and is accompanied by an increase in circulating aldosterone levels. Br J Pharmacol 2008 154 : 1465 1473.
9. Krishna R, Bergman A, Jin B, Fallon M, Cote J, Van Hoydonck P, Laethem T, Gendrano IN, Van Dyck K, Hilliard D, Laterza O, Snyder K, Chavez-Eng C, Lutz R, Chen J, Bloomfield DM, De Smet M, Van Bortel L, Gutierrez M, Al-Huniti N, Dykstra K, Gottesdiener KM, Wagner JA. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther 2008 84 : 679 683.
10. Lam FC, Hung CT, Perrier DG. Estimation of variance for harmonic mean half-lives. J Pharm Sci 1985 74 : 229 231.
11. Dalvie D, Chen W, Zheng C, Vaz AD, Smolarek TA, Cox LM, Lin J, Obach RS. Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans. Drug Metab Dispos 2008 36 : 2185 2198.
12. Hartmann G, Ngui J, Chen Q, Ortiga R, Strauss J, Ciccotto-Gilbert S, Pereira A, Bradley S, Doss G, Andrews-Kelly G, Friscino B, Gai C, Iliff S, Trinh T, Zhang A, Tang W, Kumar S, Tan EY. Metabolism and disposition of anacetrapib, a potent inhibitor of cholesteryl ester transfer protein, in rats and rhesus monkeys. Drug Metab Disp 2009 in press.
13. Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 1999 37 : 213 255.
14. Krishna R, Jensen BK. Pharmacokinetics: effects of food and fasting. Encyclopedia entry. In : Encyclopedia of Pharmaceutical Technology, 2nd edn, ed. Swarbrick J. New York : Marcel Dekker, 2003 1 13. DOI: 10.1081/E-EPT-120014401.
15. Perlman ME, Murdande SB, Gumkowski MJ, Shah TS, Rodricks CM, Thornton-Manning J, Freed D, Erhart LC. Development of a self-emulsifying formulation that reduces the food effect for torcetrapib. Int J Pharm 2007 351 : 15 22.
16. Sunami M, Serigano T. Pharmaceutical compositions of CETP inhibitors. US Patent Appl 2003 60/ 493 : 649.
17. Krishna R, Anderson MS, Bergman A, Jin B, Fallon M, Cote J, Rosko K, Chavez-Eng C, Lutz R, Bloomfield DM, Gutierrez M, Doherty J, Bieberdorf F, Chodakewitz J, Gottesdiener K, Wagner JA. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in health individuals: two double-blind, randomized placebo-controlled phase 1 studies. Lancet 2007 370 : 1907 1914.
18. Bloomfield DM, Carlson G, Sapre A, Tribble D, McKenney JM, Littlejohn TW, Sisk CM, Mitchel YB. Efficacy and safety of the CETP inhibitor anacetrapib in dyslipidemic patients. J Clin Lipidol 2007 1 : 327.
19. Fleischer D, Li C, Zhou Y, Pao L-H, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clin Pharmacokinet 1999 36 : 233 254.
20. Brown S, Rowley G, Pearson JT. Surface treatment of the hydrophobic drug danazol to improve drug dissolution. Int J Pharm 1998 165 : 227 237.
21. Bergman A, Dykstra K, Al-Huniti N, Fallon M, Lutz R, Chavez-Eng C, Jin B, Hartford A, Cote J, Hilliard D, Laethem T, Van Hoydonck P, Snyder K, Van Dyck K, Stone J, Lasseter KC, Van Bortel L, Wagner J, Krishna R. Optimizing dose selection using population PK/PD modeling and simulation for the CETP inhibitor anacetrapib (MK-0859) in healthy subjects abstract]. American Association of Pharmaceutical Scientists Annual Meeting, Anaheim, CA, 2007.
22. Bergman A, Dykstra K, Jin B, Bloomfield D, Hartford A, Fallon M, Stone J,Wagner J, Krishna R. Model-based development of anacetrapib, a novel CETP inhibitor. Clin Pharmacol Ther 2009; 85: S27 [Abstract].
23. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand TM,Wester RT, Williams JA, Perlman ME, Bamberger MJ. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arteroscler Thromb Vasc Biol 2004; 24: 490-7.